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ABSTRACT
Invasive fungal infections (IFIs) are life-threatening complications of 
hematological malignancies that must be diagnosed early to allow effective treatment. 
Few data are available on the performance of serum (1–3)-β-D-glucan (BG) assays 
for diagnosing IFI in patients with hematological malignancies admitted to the 
intensive care unit (ICU). In this study, 737 consecutive patients with hematological 
malignancies admitted to 17 ICUs routinely underwent a BG assay at ICU admission. 
IFIs were diagnosed using standard criteria applied by three independent specialists. 
Among the 737 patients, 439 (60%) required mechanical ventilation and 273 
(37%) died before hospital discharge. Factors known to alter BG concentrations 
were identified in most patients. IFIs were documented in 78 (10.6%) patients 
(invasive pulmonary aspergillosis, n = 54; Pneumocystis jirovecii pneumonia, n = 13; 
candidemia, n = 13; and fusarium infections, n = 3). BG concentrations (pg/mL) were 
higher in patients with than without IFI (144 (77–510) vs. 50 (30–125), < 0.0001). 
With 80 pg/mL as the cutoff, sensitivity was 72%, specificity 65%, and area-under-
the-curve 0.74 (0.68–0.79). Assuming a prevalence of 10%, the negative and positive 
predictive values were 94% and 21%. By multivariable analysis, factors independently 
associated with BG > 80 pg/mL were IFI, admission SOFA score, autologous bone-
marrow or hematopoietic stem-cell transplantation, and microbiologically documented 
bacterial infection. In conclusion, in unselected critically ill hematology patients with 
factors known to affect serum BG, this biomarker showed only moderate diagnostic 
performance and rarely detected IFI. However, the negative predictive value was high. 
Studies are needed to assess whether a negative BG test indicates that antifungal 
de-escalation is safe.
Oncotarget21485www.impactjournals.com/oncotarget
INTRODUCTION
Advances in the management of patients with 
hematological malignancies have led to improved 
survival, but have also increased the incidence of invasive 
fungal infections (IFIs). [1] despite the widespread use 
of prophylactic antifungal agents. Early recognition 
and treatment of life-threatening IFIs in patients with 
hematological malignancies is crucial [2]. Both cultures 
and imaging studies often fail to establish the definitive 
diagnosis of specific IFIs, leading to prolonged empirical 
antifungal therapy, whose effectiveness may be limited 
[1, 3].
IFIs carry a grim prognosis in patients with 
hematological malignancies admitted to the ICU, 
particularly those receiving mechanical ventilation 
or having a history of allogeneic bone-marrow or 
hematopoietic stem-cell transplantation [4]. In these 
patients, co-infections [5] and organ dysfunctions are 
common and may impair the performance of diagnostic 
biomarkers for IFIs [6, 7].
Plasma (1, 3)-β-D-glucan (BG) antigenemia 
is among the revised criteria for IFI and probable IFI 
developed by the European Organization for Research 
and Treatment of Cancer and Mycoses Study Group 
(EORTC-MSG) [1, 8]. BG is a cell-wall component of 
most fungi responsible for IFIs, except Zygomycetes spp. 
and Cryptococcus spp. The assay relies on activation 
by BG of factor G in the coagulation cascade in the 
Limulus amebocyte lysate, which leads to quantifiable 
transformation of a chromogenic substrate [9]. BG 
has been evaluated using various study designs, in 
different settings. In case-control studies comparing 
patients with proven or probable IFI to healthy controls 
or patient populations at low risk for IFI, BG assay 
was 50%–90% sensitive and 70%–100% specific [10–
13]. Performance was better in prospective studies 
of homogeneous populations at high risk for IFI [14, 
15] but differed markedly between patients with acute 
leukemia and recipients of allogeneic hematopoietic 
stem-cell transplants (HSCT). In an autopsy-based 
study of 47 critically ill immunocompromised patients 
(including 17 with hematological malignancies) at risk 
for invasive aspergillosis (IA), serum BG levels were 
significantly higher in patients with IA than in those 
with no IFI [16]. However, overall performance of BG 
was moderate and 2 patients with bacteremia had serum 
BG levels higher than 140 pg/mL [16]. In a retrospective 
study, BG increased the rate of IA detection compared 
to galactomannan [13]. Importantly, BG was positive in 
all patients with Pneumocystis jirovecii pneumonia and 
in 85% of those with fungal bloodstream infections [13]. 
A metaanalysis that excluded patients with P. jirovecii 
infection showed a sensitivity of 76.8% (95% confidence 
interval, [95% CI], 67.1%–84.3%) and a specificity of 
85.3% (95% CI, 79.6–89.7) [17]. Another metaanalysis 
focused on patients with hematological malignancies 
(n = 1771, including 414 with IFIs) and showed that 
two consecutive positive BG assays had very good 
specificity (98.9%; 95%CI, 97.4%–99.5%), positive 
predictive value (PPV, 83.5% for a prevalence of 
10%), and negative predictive value (NPV, 94.6% for a 
prevalence of 10%) for proven or probable IFI. However, 
sensitivity was low (49.6%; 95% CI, 34.0%–65.3%) 
[18]. Performance was similar across the different BG 
assays [18].
No study has evaluated how BG contributes to the 
diagnosis of IFI in unselected patients with hematological 
malignancies admitted to the ICU. These patients 
usually have organ dysfunctions, which may affect 
BG performance; [4] and bacterial infections, which 
complicate the interpretation of BG assay results [13, 
16]. Furthermore, over 90% of critically ill hematology 
patients receive antibacterial agents and up to 50% 
antifungal agents, which have been reported to modify 
BG values [19].
The objective of this multicenter database study 
conducted by the Groupe de Recherche en Réanimation 
respiratoire Onco-Hématologique (Grrr-OH) was to 
assess the accuracy of BG for diagnosing IFI in unselected 
critically ill patients with hematological malignancies. 
RESULTS
Patients
As shown in Figure 1, of 1011 patients with 
hematological malignancies admitted to the study ICUs, 
801 were admitted on weekdays and 737 were included 
in the study. These 737 patients showed no significant 
differences with the 274 patients who were not included. 
Two patients with Zygomycetes infections were not 
included.
Table 1 reports the main patient characteristics. 
Acute leukemia and non-Hodgkin lymphoma were the 
most common malignancies and 80% of patients had 
received chemotherapy in the past week, whereas only 
174 (23.6%) were in partial or complete remission. The 
malignancy had been diagnosed in the past 2 weeks in 
283 (38.4%) patients. Of the 184 (25%) bone-marrow 
transplant (BMT) or HSCT recipients, 81 had received 
autologous and 103 allogeneic transplants. Neutropenia 
at ICU admission was found in 208 (28%) patients. The 
main reason for ICU admission was acute respiratory 
failure (n = 398, 54%), and mechanical ventilation 
was provided to 439 (60%) patients. Hospital mortality 
was 37%.
IFIs were documented in 78 (10.6%) patients, 
including 54 with IPA (5 proven, 31 probable, and 
18 possible), 13 with proven P. jirovecii pneumonia, 
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13 with candidemia, and 3 with fusarium infections; 
5 patients had both candidemia and another IFI. Mortality 
in patients without IFI was 35.1%, rising to 64.8% in 
patients with invasive aspergillosis (OR 3.41 (1.91–6.10)).
(1–3)-β-D-glucan (BG) assay results
Median (25th–75th) BG concentration was 62 
(37–120) pg/mL, and 32% of patients had BG 
concentrations above the manufacturer’s cutoff (80 pg/mL). 
BG concentrations were higher in patients with than 
without IFI (144 [77–510] vs. 50 [30–125], P < 0.0001). 
Of the 78 patients with IFIs, 74.4% had BG > 80 pg/mL 
(Figure 2A). However, BG was also > 80 pg/mL in 38.3% 
of patients with bacterial infections and 30.7% with 
noninfectious diseases (P < 0.0001). Figure 2B shows 
BG results according to type of IFI. BG was < 80 pg/mL 
in 2 patients with Pneumocystis pneumonia, 3 patients 
with candidemia, and 30% of patients with IPA. BG 
was > 80 pg/mL in 35% of patients without IFIs. 
Diagnostic performance of the (1–3)-β-D-glucan 
(BG) assay
Figure 3 displays the performance characteristics of 
the BG assay. The manufacturer’s cutoff of 80 pg/mL was 
associated with the best performance, with 72% sensitivity, 
65% specificity, and a ROC-AUC of 0.74 (0.68–0.79). The 
sensitivity analyses showed no differences in performance 
characteristics in patients with IA (Supplementary Figure S1) 
or with acute respiratory failure, or allogeneic BMT/HSCT 
(data not shown). Additional sensitivity analyses were 
performed to assess the performance of a BDG > 80 pg/
ml in different subgroups. It did not disclose any difference 
patients without neutropenia (AUC = 0.752 (0.678–0.826)), 
those not needing mechanical ventilation (AUC 0.778 
(0.693–0.862)), or vasopressors (AUC 0.796 (0.715–0.877)).
Furthermore, antifungal treatment at ICU admission 
did not affect BG assay performance (ROC-AUCs: all 
patients, 0.74 [0.68–0.79]; patients without antifungal 
therapy, 0.72 [0.61–0.83]; and patients with antifungal 
Figure 1: Patient flowchart (5 patients had both candidemia and another IFI).
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Table 1: Patient characteristics at ICU admission
IFI
n = 78
No IFI
n = 659 P value
Age 58 (48–64) 61 (50–70) 0.08
Male gender 46 (59.0%) 397 (60.2%) 0.83
Underlying malignancy
Non-Hodgkin lymphoma 
Acute myeloid leukemia
Myeloma
Acute lymphocytic leukemia
Chronic lymphocytic leukemia
Chronic myeloid leukemia
Myelodysplastic syndrome
Hodgkin lymphoma
Other malignancies 
23 (29.5%)
20 (25.6%)
7 (9.0%)
9 (11.5%)
5 (6.4%)
2 (2.6%)
1 (1.3%)
3 (3.8%)
8 (10.3%)
209 (31.7%)
180 (27.3%)
90 (13.7%)
40 (6.1%)
57 (8.6%)
13 (2.0%)
20 (3.0%)
14 (2.1%)
36 (5.5%)
0.37
Newly diagnosed malignancy ¥ 22 (28.2%) 261 (39.6%) 0.06
Partial or complete remission 19 (24.4%) 155 (23.5%) 0.88
BMT / HSCT
No
Autologous
Allogeneic 
49 (62.8%)
11 (14.1%)
18 (23.1%)
504 (76.5%)
 70 (10.6%) 
 85 (12.9%)
0.02
Chemotherapy in the last 7 days 72 (92.3%) 519 (78.8%) 0.004
Neutropenia 34 (43.6%) 174 (26.4%) 0.002
Reasons for ICU admission £
Acute respiratory failure
Shock
Acute renal failure
Sepsis
69 (88.5%)
52 (66.7%)
9 (11.5%)
78 (100%)
329 (49.9%)
308 (46.7%)
146 (22.2%)
398 (60.4%)
 < 0.0001
0.001
0.03
 < 0.0001
Systemic antifungal agents 59 (76%) 224 (34%)  < 0.0001
Life-sustaining therapies
Mechanical ventilation (invasive 
or noninvasive)
Vasopressors
Renal replacement therapy
65 (83.3%)
52 (66.7%)
22 (28.6%)
374 (56.8%)
308 (46.7%)
167 (26.0%)
0.02
0.001
0.73
Outcomes
Length of ICU stay
ICU mortality
Length of hospital stay
Hospital mortality
9 (5–17)
32 (41.0%)
9 (5–17)
42 (53.8%)
5 (3–10)
158 (24.0%)
5 (3–10)
231 (35.1%)
 < 0.0001
0.002
 < 0.0001
0.002
BG concentrations (pg/mL) were 
higher in patients with than  
without IFI (144 (77–510) vs. 50 
(30–125), < 0.0001)
144 (77–510) 50 (30–125)  < 0.0001
¥ Hematological malignancy diagnosed in the past 2 weeks. 
£ Some patients were admitted for more than one reason. 
IFI, invasive fungal infection; BMT, bone marrow transplant; HSCT, hematopoietic stem-cell transplant; ICU, intensive 
care unit; BG, (1–3)-β-D-glucan.
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Figure 2: β-D-glucan concentrations (box plots, Y axis on the left) and proportion of patients with β-D-glucan > 80 pg/mL 
(▼, Y axis on the right) according to final diagnoses. (A) β-D-glucan was > 80 pg/mL not only in 74.4% of patients with 
invasive fungal infections, but also in 38.3% with bacterial infections and 30.7% with noninfectious diseases (P < 0.0001). (B) β-D-glucan 
was < 80 pg/mL in 2 patients with Pneumocystis pneumonia, 3 patients with candidemia, and 30% of patients with invasive pulmonary 
aspergillosis. On the opposite, β-D-glucan was > 80 pg/mL in 30% of patients without fungal infections. Patients with Fusarium infection 
had β-D-glucan concentrations of 76 pg/mL [75–77].
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therapy, 0.73 [0.66–0.80]). With a 10% prevalence of IFI, 
NPV was 94% and PPV 21% (Supplementary Figure S2). 
The contribution of a BG > 80 pg/mL to estimating the 
pre-test probability of IFI was fair. For instance, a 40% 
pre-test probability of IFI was increased to 58% by a 
positive BG assay and decreased to 22% by a negative 
BG assay (Supplementary Table S1 and Supplementary 
Figure S3).
Factors affecting (1–3)-β-D-glucan (BG) assay 
results 
Table 2 reports the multivariable analysis of factors 
independently associated with a positive BG ( > 80 pg/mL). 
IFI was associated with a positive BG (OR, 4.42 [95%CI, 
2.57–7.75]), as well as admission SOFA score, autologous 
BMT/HSCT, and microbiologically documented bacterial 
infection. When neutropenia was forced into the final 
model, this variable was not selected and did not change 
the results.
Estimated clinical impact of the (1–3)-β-D-
glucan (BG) assay
Among the 78 patients with a final diagnosis of 
IFI, only 59 (76%) received systemic antifungals during 
the ICU stay; thus, 19 (24%) patients with IFI were left 
untreated. Had the BG assay results been communicated 
to the managing physicians and treatment given when 
(and only when) BG was > 80 pg/mL, then 12 of these 
19 patients would have received antifungals but 15 
of the 59 treated patients with IFIs would have had 
their antifungals withdrawn. Among the 659 patients 
without IFI, 145 would have received antifungal therapy 
and 135 would have had their antifungal therapy 
withdrawn. Figure 4 reports the relation between hospital 
mortality, BG concentrations, and antifungal therapy. 
Antifungal agents were administered to 46% of patients 
with BG > 80 pg/mL and to 33% of patients with 
BG < 80 pg/mL. Figure 4 shows significant differences 
in hospital mortality across patient groups defined by BG 
concentrations and use of systemic antifungals. 
DISCUSSION
The (1, 3)-β-D-glucan assay has been recommended 
for diagnosing IFIs in high-risk patients with 
hematological malignancies [1]. This assay has been used 
to guide clinical management decisions in conjunction 
with clinical, microbiological, and radiological findings 
[8]. However, the diagnostic accuracy and optimal cutoff 
of the BG assay in unselected critically ill hematology 
patients remain unclear. We evaluated these two points 
in a population that reflects everyday clinical practice. 
Furthermore, our sample size was sufficiently large to 
allow separate assessments of diagnostic accuracy in 
Figure 3: Performance of (1–3)-β-D-glucan for the diagnosis of invasive fungal infection (area under the ROC curve 
according to BG value). Sensitivity and sensitivity are reported for (1–3)-β-D-glucan cutoffs of 60 pg/mL, 80 pg/mL, and 100 pg/mL. 
The best cutoff was 80 pg/mL.
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high-risk patients (i.e., patients with acute leukemia and 
prolonged neutropenia after induction/consolidation 
chemotherapy or allogeneic HSCT) and in various types 
of fungal infections. 
Many of the factors reported to impair the 
performance of the BG assay are frequently present in 
critically ill patients. False-negative BG results occur 
in patients receiving antifungal agents and in those with 
IFIs due to organisms not detected by the BG assay 
[10]. However, in our study, BG concentrations were not 
affected by prophylactic or curative antifungal therapy. 
Moreover, we did not include patients with IFI due to 
Zygomycetes, which is not detected by the BG assay. 
Factors associated with false-positive BG results include 
blood transfusions or administration of blood products 
[1] (70% of our patients), renal replacement therapy [7] 
(27%), β-lactam antibiotics (90%) and bacterial infection 
(53%) [26]. These factors may explain the limited 
sensitivity and specificity of the BG assay in critically ill 
hematology patients in our study. 
The contribution of the BG assay to the diagnosis 
of IFI in our population was modest: sensitivity and 
PPV were low, and the increase in pre-test probability 
of IFI was moderate. However, the good NPV of the 
BG assay suggests a possible role in deciding antifungal 
agent de-escalation in high-risk patients with low pre-
test probability. With antibacterial agents, de-escalation 
has been found feasible and safe in general ICU patients 
[27, 28] and in ICU patients with neutropenia [29]. 
Fungal infections are associated with high morbidity 
and mortality rates in hematology patients. Establishing 
a definitive diagnosis of IFI is difficult. The signs and 
symptoms are nonspecific and may not develop until the 
disease is advanced or disseminated. Antifungal agents 
are therefore given prophylactically or pre-emptively 
in high-risk patients. Withdrawing unnecessary 
antifungal therapy decreases the risk of toxicity and 
drug interactions and diminishes healthcare costs. 
Studies are needed to determine whether the BG assay 
is effective and safe in guiding decisions to de-escalate 
Table 2: Multivariable analysis of factors associated with a (1–3)-β-D-glucan concentration > 80 pg/mL
Variable
Odds 
ratio
95% 
confidence interval
P
value
SOFA score at ICU admission 1.06 per point 1.02–1.11 0.009
Autologous BMT/HSCT 1.56 1.07–2.29 0.02
Invasive fungal infection 4.42 2.57–7.75  < 0.0001
Documented bacterial infection 1.41 0.96–2.07 0.08
Hossmer Lemeshow Chi-square: 11.07; df = 8, P = 0.20.
Figure 4: Hospital mortality according to (1–3)-β-D-glucan concentrations and antifungal therapy in the ICU. 
P < 0.0001 across the four groups.
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antifungal therapy in ICU patients with hematological 
malignancies. 
In our study, among patients with BG > 80 pg/mL 
who received antifungal agents, 55% died. This rate 
is significantly higher than mortality rates in patients 
with either low BG or no antifungal therapy but is 
nevertheless considerably lower than previously reported 
in critically ill hematology patients with IFIs. Overall 
mortality in patients with IFIs was 53.8%. This suggests 
that the physicians in the 17 participating ICUs, who 
were blinded to BG results, maintained a high level of 
suspicion regarding IFI. This possibility is consistent with 
an autopsy study showing that the proportion of patients 
who received antifungal agents but had no IFI was larger 
than the proportion who died from untreated IFI [30]. This 
point further supports the need for studies of antifungal 
agent withdrawal in patients with no proof of IFI and low 
BG levels.
This study has several limitations. First, BG 
was assayed only once, at ICU admission. Serial 
measurements of fungal cell-wall biomarkers may be 
more effective both for diagnosing IFI and for assessing 
the therapeutic response. However, this study is the 
first to assess the diagnostic accuracy of the BG assay 
in a large cohort of critically ill hematology patients. 
Second, we did not focus on a single fungal infection. 
However, we analyzed the patients with IA separately 
and found that the performance of the BG assay in this 
subgroup was similar to that in the overall population. 
Nevertheless, whereas the BG assay was previously 
reported to be consistently positive in patients with P. 
jirovecii pneumonia, 2 such patients had a negative 
BG assay in our study. A careful assessment of pre-
test probabilities of each etiology is essential, and the 
BG assay should be interpreted in the light of a broad 
array of clinical, laboratory, and imaging findings. 
Last, etiological diagnoses were made by consensus 
among three independent experts, based on the most 
recent diagnostic criteria for IFI. However, these criteria 
may lack sensitivity, and some patients with high BG 
concentrations who were classified as not having IFI 
may have had undiagnosed IFI. In patients with febrile 
neutropenia and lung infiltrates, combining multiple 
diagnostic tests, including PCR assays, provided only 
modest increases in the sensitivity and PPV predictive 
value of the BG assay [19]. Moreover, BG levels were 
higher in patients with IFI proven by autopsy than in 
patients without IFI [16].
In conclusion, the diagnostic usefulness of 
BG concentrations in critically ill patients with 
hematological malignancies is limited by low sensitivity 
and specificity. However, the good NPV may warrant 
studies to assess the usefulness of the BG assay for 
identifying patients whose antifungal treatment can be 
safely withdrawn. 
PATIENTS AND METHODS
Patients
We studied patients from the Grrr-OH database 
described in a previous publication [4]. Consecutive 
adults ( > 18 years) with hematological malignancies 
admitted to 17 ICUs in France and Belgium over a 
16-month period in 2010–2011 were included into the 
database (ClinicalTrials.gov Identifier:NCT01172132). 
As described previously [4], we excluded patients who 
had been disease-free for more than 5 years or were 
admitted to the ICU only to undergo a procedure under 
optimal safety conditions. The study was approved by the 
appropriate ethics committees in France and Belgium. All 
patients or relatives gave their informed consent to study 
participation. 
Data collection
In each center, an investigator recorded the study 
data on a standardized electronic case-report form. In all 
17 centers, a senior intensivist and a senior hematologist 
were available around the clock and made decisions 
together. All diagnostic strategies and antifungal 
treatment decisions were based on clinical judgment, 
according to standard practice in the Grrr-OH research 
group. 
The data in the tables and figures were collected 
prospectively. The Sepsis-Related Organ Failure 
Assessment (SOFA) score was computed at admission 
[20] to estimate the risk of death based on organ 
dysfunctions. Reasons for ICU admission were recorded 
based on the main symptoms at ICU admission [21]. 
Acute respiratory failure was defined as previously 
reported [22, 23] and neutropenia as a neutrophil 
count < 500/mm3 [24]. Prespecified criteria were 
applied to define the causes of pulmonary involvement; 
[5] for possible or probable IA, the most recent 
definitions were used [1]. Candidemia was defined 
as recovery of any Candida species from at least one 
blood culture [25]. Invasive fusarium infections were 
documented by blood culture or skin biopsy. Confirmed 
Pneumocystis pneumonia was presence of P. jirovecii 
by Gomori-Grocott or toluidine-blue stain, or a positive 
immunofluorescence test, on bronchoalveolar lavage 
(BAL) fluid or induced sputum. Mucormycoses were 
documented as previously described [1].
Etiological diagnosis
Etiologic diagnoses were these that required the 
need for ICU admission and present at the time the 
patients was sampled for BG dosage. They were made by 
consensus among the managing physicians (intensivists, 
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hematologists, and consultants), according to recent 
definitions [4, 5]. Only IFIs present at ICU admission or 
in the first 5 days of ICU admission were considered. For 
the study, the diagnosis in each patient was reevaluated by 
three independent experienced intensivists (EA, FV, VL) 
who were blinded to the initial diagnosis and had access 
to all the clinical and microbiological data. They disagreed 
with the managing physicians for 87 patients, 70 with non-
fungal etiologies and 17 with IFIs. Of these 17 patients, 
6 had microbiological samples that became positive after 
their death (3 candidemia and 3 Aspergillus in the lower 
respiratory tract), 5 were reclassified as having probable 
instead of possible invasive pulmonary aspergillosis [IPA], 
2 with a PCR-based diagnosis of Pneumocystis pneumonia 
were reclassified as having Pneumocystis colonization, 
and 4 with possible IPA were reclassified as having no 
identifiable cause (2 had pulmonary findings consistent 
with leukemic infiltrates but no CT scan and were quickly 
discharged from the ICU and 2 had normal CT scans). 
These disagreements were resolved by consensus between 
the main investigator and the investigator at the relevant 
study center. 
(1–3)-β-D-glucan assay
All patients admitted on weekdays had an arterial 
and/or venous blood sample taken at admission for a BG 
assay. The serum was processed within 6 h of collection 
then stored at −20°C until batch testing was performed. 
The BG assay Fungitell® (Associates of Cape Cod Inc., 
Falmouth¸ MA, USA) was used as recommended by the 
manufacturer, with the ELx808™ Absorbance Microplate 
Reader and Gen5™ Data Analysis Software (Biotek 
Instruments, Winooski, VT, USA). The BG concentration 
in each sample was calculated automatically using a 
calibration curve established from standard solutions 
containing 31.25 pg/mL to 500 pg/mM of BG. We 
evaluated the manufacturer-recommended BG cutoff of 
80 pg/mL and other cutoff values. All materials used for 
the assay were glucan-free. Each sample was assayed 
in triplicate, and the mean of the three values was used 
for the study. When one of the three values differed 
markedly from the other two, it was discarded, provided 
the other two results had a coefficient of variation ≤ 20% 
for BG concentrations below 200 pg/mL; for higher BG 
concentrations, the assay was repeated if the coefficient of 
variation was > 100%. The assay results were not reported 
to the managing physicians.
Statistical analysis
Continuous variables were described as medians 
(25th–75th quartiles) and compared using the Mann-
Whitney U test. Categorical variables were described 
as percentages and compared using the two-tailed χ2 
test or Fisher’s exact test, as appropriate. The following 
parameters of diagnostic performance and their 95%CIs 
were calculated: sensitivity, specificity, PPV, NPV, and 
Cohen’s kappa. The discriminatory power of BG was 
evaluated by computing areas under the receiver-operating 
characteristic curves (ROC-AUCs), which were compared 
as described by Hanley and McNeil. 
We performed logistic regression analyses to 
identify variables significantly associated with BG 
concentrations > 80 pg/mL, by estimating the odds ratio 
(OR) with the 95%CI. Variables yielding P values lower 
than 0.20 by univariate analyses or considered clinically 
relevant were entered into a backward stepwise logistic 
regression model. We checked that continuous variables 
were log-linear. The covariates were entered into the 
model with critical entry and removal P values of 0.20 
and 0.1, respectively. Multicollinearity and interactions 
were tested. The Hosmer-Lemeshow test was used to 
check goodness-of-fit of the logistic regression model. 
Last, because neutropenia is a major clinical risk factor 
and confounder for fungal infection in patients with 
hematological malignancies, the predefined statistical 
analysis plan involved forcing this variable into the final 
model in the event it was not selected. All tests were 
two-sided, and P values lower than 0.05 were considered 
statistically significant. Statistical tests were done using 
the SPSS 13 software package (IBM, Armonk, NY, USA).
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Summary
A single (1, 3)-β-D-glucan assay at ICU admission 
of patients with hematological malignancies makes only 
a modest contribution to the diagnosis of invasive fungal 
infection but, when negative, may indicate that prophylactic/
pre-emptive antifungals can be withdrawn safely.
Abbreviations list
95%CI, 95% confidence interval
AUC, area under the curve
BAL, bronchoalveolar lavage
BG, (1–3)-β-D-glucan
BMT, bone marrow transplant
CT, computed tomography
EORTC, European Organization for Research and 
Treatment of Cancer Mycoses Study Group
Grrr-OH, Groupe de Recherche en Réanimation 
respiratoire Onco-Hématologique (oncology-hematology 
respiratory research group)
HM, hematological malignancies
HSCT, hematopoietic stem-cell transplant
ICU, intensive care unit
IFI, invasive fungal infection
MSG, Mycoses Study Group
NPV, negative predictive value
OR, odds ratio
PCR, polymerase reaction chain
PPV, positive predictive value
ROC, receiver-operating characteristic
SOFA, Sequential Organ Failure Assessment
Authors’ contributions 
EA had full access to all of the data in the study and takes 
responsibility for the integrity of the data and the accuracy 
of the data analysis. 
EA conceived and designed the study; collected, analyzed, 
and interpreted the data; and wrote the manuscript
NG designed the study; collected, analyzed, and 
interpreted the data; and wrote the manuscript
MD collected, analyzed, interpreted data and revised the 
manuscript for important intellectual content
DM collected, analyzed, interpreted data and revised the 
manuscript for important intellectual content
VL conceived and designed the study, included patients 
and help in data interpretation. 
AK collected, analyzed, interpreted data and revised the 
manuscript for important intellectual content
JM collected, analyzed, interpreted data and revised the 
manuscript for important intellectual content
FV collected, analyzed, interpreted data and revised the 
manuscript for important intellectual content
MN collected, analyzed, interpreted data and revised the 
manuscript for important intellectual content
FB collected, analyzed, interpreted data and revised the 
manuscript for important intellectual content
AR collected, analyzed, interpreted data and revised the 
manuscript for important intellectual content
SB collected, analyzed, interpreted data and revised the 
manuscript for important intellectual content
CL collected, analyzed, interpreted data and revised the 
manuscript for important intellectual content
APM collected, analyzed, interpreted data and revised the 
manuscript for important intellectual content
DB collected, analyzed, interpreted data and revised the 
manuscript for important intellectual content
FP collected, analyzed, interpreted data and revised the 
manuscript for important intellectual content
CONFLICTS OF INTEREST
M. Darmon lectured for MSD, Gilead, Bristol-
Myers Squibb, and Astellas. His institution received grant 
support from MSD and Astute Medical.
E Azoulay lectured for MSD, Astellas, Gilead and 
Alexion. His institution received research grants from 
Pfizer, Gilead, MSD, Cubist and Fisher & Paeckle.
All other authors declare no conflicts of interest. 
REFERENCES
 1. De Pauw B, Walsh TJ, Donnelly JP, Stevens DA, Edwards 
JE, Calandra T, Pappas PG, Maertens J, Lortholary O, 
Kauffman CA, Denning DW, Patterson TF, Maschmeyer G, 
et al. Revised definitions of invasive fungal disease from 
the European Organization for Research and Treatment of 
Oncotarget21494www.impactjournals.com/oncotarget
Cancer/Invasive Fungal Infections Cooperative Group and 
the National Institute of Allergy and Infectious Diseases 
Mycoses Study Group (EORTC/MSG) Consensus Group. 
Clin Infect Dis 2008; 46:1813–21.
 2. Neofytos D, Horn D, Anaissie E, Steinbach W, Olyaei A, 
Fishman J, Pfaller M, Chang C, Webster K, Marr K. 
Epidemiology and outcome of invasive fungal infection in 
adult hematopoietic stem cell transplant recipients: analysis 
of Multicenter Prospective Antifungal Therapy (PATH) 
Alliance registry. Clin Infect Dis 2009; 48:265–73.
 3. Freifeld AG, Bow EJ, Sepkowitz KA, Boeckh MJ, Ito JI, 
Mullen CA, Raad, II, Rolston KV, Young JA, Wingard JR, 
Infectious Diseases Society of A. Clinical practice guideline 
for the use of antimicrobial agents in neutropenic patients 
with cancer: 2010 update by the infectious diseases society 
of america. Clin Infect Dis 2011; 52:e56–93
 4. Azoulay E, Mokart D, Pene F, Lambert J, Kouatchet A, 
Mayaux J, Vincent F, Nyunga M, Bruneel F, Laisne LM, 
Rabbat A, Lebert C, Perez P, et al. Outcomes of critically 
ill patients with hematologic malignancies: prospective 
multicenter data from France and Belgium—a groupe de 
recherche respiratoire en reanimation onco-hematologique 
study. J Clin Oncol 2013; 31: 2810–8
 5. Azoulay E, Mokart D, Lambert J, Lemiale V, Rabbat A, 
Kouatchet A, Vincent F, Gruson D, Bruneel F, Epinette-
Branche G, Lafabrie A, Hamidfar-Roy R, Cracco C, et al. 
Diagnostic strategy for hematology and oncology patients 
with acute respiratory failure: randomized controlled trial. 
Am J Respir Crit Care Med 2010; 182:1038–46
6. Mohr JF, Sims C, Paetznick V, Rodriguez J, Finkelman MA, 
Rex JH, Ostrosky-Zeichner L: Prospective survey of 
(1 – > 3)-beta-D-glucan and its relationship to invasive 
candidiasis in the surgical intensive care unit setting. J Clin 
Microbiol 2011; 49:58–61.
7. Kato A, Takita T, Furuhashi M, Takahashi T, Maruyama Y, 
Hishida A: Elevation of blood (1 – > 3)-beta-D-glucan 
concentrations in hemodialysis patients. Nephron 2001; 89: 
15–9.
8. Marchetti O, Lamoth F, Mikulska M, Viscoli C, Verweij P, 
Bretagne S: ECIL recommendations for the use of biological 
markers for the diagnosis of invasive fungal diseases in 
leukemic patients and hematopoietic SCT recipients. Bone 
Marrow Transplant 2012; 47: 846–54.
9. Obayashi T, Yoshida M, Tamura H, Aketagawa J, Tanaka S, 
Kawai T: Determination of plasma (1 – > 3)-beta-D-glucan: 
a new diagnostic aid to deep mycosis. J Med Vet Mycol 
1992; 30: 275–80.
10. Obayashi T, Negishi K, Suzuki T, Funata N: Reappraisal of 
the serum (1 – > 3)-beta-D-glucan assay for the diagnosis of 
invasive fungal infections—a study based on autopsy cases 
from 6 years. Clin Infect Dis 2008; 46: 1864–70.
11. Hachem RY, Kontoyiannis DP, Chemaly RF, Jiang Y, 
Reitzel R, Raad I: Utility of galactomannan enzyme 
immunoassay and (1, 3) beta-D-glucan in diagnosis of 
invasive fungal infections: low sensitivity for Aspergillus 
fumigatus infection in hematologic malignancy patients. 
J Clin Microbiol 2009; 47: 129–33.
12. Ostrosky-Zeichner L, Alexander BD, Kett DH, Vazquez J, 
Pappas PG, Saeki F, Ketchum PA, Wingard J, Schiff R, 
Tamura H, Finkelman MA, Rex JH: Multicenter clinical 
evaluation of the (1 – > 3) beta-D-glucan assay as an aid 
to diagnosis of fungal infections in humans. Clin Infect Dis 
2005; 41: 654–9.
13. Persat F, Ranque S, Derouin F, Michel-Nguyen A, Picot S, 
Sulahian A. Contribution of the (1 – > 3)-beta-D-glucan 
assay for diagnosis of invasive fungal infections. J Clin 
Microbiol 2008; 46:1009–13.
14. Odabasi Z, Mattiuzzi G, Estey E, Kantarjian H, Saeki F, 
Ridge RJ, Ketchum PA, Finkelman MA, Rex JH, Ostrosky-
Zeichner L. Beta-D-glucan as a diagnostic adjunct for 
invasive fungal infections: validation, cutoff development, 
and performance in patients with acute myelogenous 
leukemia and myelodysplastic syndrome. Clin Infect Dis 
2004; 39: 199–205.
15. Senn L, Robinson JO, Schmidt S, Knaup M, Asahi N, 
Satomura S, Matsuura S, Duvoisin B, Bille J, Calandra T, 
Marchetti O. 1,3-Beta-D-glucan antigenemia for early 
diagnosis of invasive fungal infections in neutropenic 
patients with acute leukemia. Clin Infect Dis 2008; 46: 
878–85.
16. De Vlieger G, Lagrou K, Maertens J, Verbeken E, 
Meersseman W, Van Wijngaerden E, Obayashi T, Negishi K, 
Suzuki T, Funata N. Beta-D-glucan detection as a diagnostic 
test for invasive aspergillosis in immunocompromised 
critically ill patients with symptoms of respiratory 
infection: an autopsy-based study Reappraisal of the serum 
(1 – > 3)-beta-D-glucan assay for the diagnosis of invasive 
fungal infections—a study based on autopsy cases from 
6 years. J Clin Microbiol 2011; 49:3783–7.
17. Karageorgopoulos DE, Vouloumanou EK, Ntziora F, 
Michalopoulos A, Rafailidis PI, Falagas ME. beta-D-glucan 
assay for the diagnosis of invasive fungal infections: a 
meta-analysis. Clin Infect Dis 2011; 52:750–70.
18. Lamoth F, Cruciani M, Mengoli C, Castagnola E, 
Lortholary O, Richardson M, Marchetti O. beta-Glucan 
antigenemia assay for the diagnosis of invasive fungal 
infections in patients with hematological malignancies: a 
systematic review and meta-analysis of cohort studies from 
the Third European Conference on Infections in Leukemia 
(ECIL-3). Clin Infect Dis 2012; 54:633–43.
19. Maschmeyer G, Carratala J, Buchheidt D, Hamprecht 
A, Heussel CP, Kahl C, Lorenz J, Neumann S, Rieger C, 
Ruhnke M, Salwender H, Schmidt-Hieber M, Azoulay E. 
Diagnosis and antimicrobial therapy of lung infiltrates in 
febrile neutropenic patients (allogeneic SCT excluded): 
updated guidelines of the Infectious Diseases Working 
Party (AGIHO) of the German Society of Hematology and 
Medical Oncology (DGHO). Ann Oncol 2014; 26:21–33.
20. Vincent JL, Moreno R, Takala J, Willatts S, De Mendonca A, 
Bruining H, Reinhart CK, Suter PM, Thijs LG. The SOFA 
Oncotarget21495www.impactjournals.com/oncotarget
(Sepsis-related Organ Failure Assessment) score to describe 
organ dysfunction/failure. On behalf of the Working Group 
on Sepsis-Related Problems of the European Society of 
Intensive Care Medicine. Intensive Care Med 1996; 22: 
707–10.
21. Dellinger RP, Levy MM, Rhodes A, Annane D, Gerlach 
H, Opal SM, Sevransky JE, Sprung CL, Douglas IS, 
Jaeschke R, Osborn TM, Nunnally ME, Townsend SR, et 
al. Surviving Sepsis Campaign: international guidelines 
for management of severe sepsis and septic shock, 2012. 
Intensive Care Med 2013; 39:165–228.
22. Azoulay E, Lemiale V, Mokart D, Pene F, Kouatchet A, 
Perez P, Vincent F, Mayaux J, Benoit D, Bruneel F, Meert 
AP, Nyunga M, Rabbat A, et al. Acute respiratory distress 
syndrome in patients with malignancies. Intensive Care 
Med 2014; 40:1106–14.
23. Hernu R, Wallet F, Thiolliere F, Martin O, Richard JC, 
Schmitt Z, Wallon G, Delannoy B, Rimmele T, Demaret C, 
Magnin C, Vallin H, Lepape A, et al. An attempt to validate 
the modification of the American-European consensus 
definition of acute lung injury/acute respiratory distress 
syndrome by the Berlin definition in a university hospital. 
Intensive Care Med 2013; 39: 2161–70.
24. Mokart D, Darmon M, Resche-Rigon M, Lemiale V, Pene 
F, Mayaux J, Rabbat A, Kouatchet A, Vincent F, Nyunga M, 
Bruneel F, Lebert C, Perez P, et al. Prognosis of neutropenic 
patients admitted to the intensive care unit. Intensive Care 
Med 2015; 41:296–303.
25. Lortholary O, Renaudat C, Sitbon K, Madec Y, Denoeud-
Ndam L, Wolff M, Fontanet A, Bretagne S, Dromer F. 
Worrisome trends in incidence and mortality of candidemia 
in intensive care units (Paris area, 2002-2010). Intensive 
Care Med 2014; 40:1303–12.
26. Albert O, Toubas D, Strady C, Cousson J, Delmas C, 
Vernet V, Villena I: Reactivity of (1 – > 3)-beta-d-glucan 
assay in bacterial bloodstream infections. Eur J Clin 
Microbiol Infect Dis 2011; 30:1453–60.
27. Leone M, Bechis C, Baumstarck K, Lefrant JY, Albanese J, 
Jaber S, Lepape A, Constantin JM, Papazian L, Bruder N, 
Allaouchiche B, Bezulier K, Antonini F, et al. De-escalation 
versus continuation of empirical antimicrobial treatment 
in severe sepsis: a multicenter non-blinded randomized 
noninferiority trial. Intensive Care Med 2014; 40:1399–408.
28. Garnacho-Montero J, Gutierrez-Pizarraya A, Escoresca-
Ortega A, Corcia-Palomo Y, Fernandez-Delgado E, 
Herrera-Melero I, Ortiz-Leyba C, Marquez-Vacaro JA. 
De-escalation of empirical therapy is associated with lower 
mortality in patients with severe sepsis and septic shock. 
Intensive Care Med 2014; 40: 32–40.
29. Mokart D, Slehofer G, Lambert J, Sannini A, Chow-
Chine L, Brun JP, Berger P, Duran S, Faucher M, Blache JL, 
Saillard C, Vey N, Leone M. De-escalation of antimicrobial 
treatment in neutropenic patients with severe sepsis: results 
from an observational study. Intensive Care Med 2014; 
40:41–9.
30. Sharma S, Nadrous HF, Peters SG, Tefferi A, Litzow MR, 
Aubry MC, Afessa B. Pulmonary complications in adult 
blood and marrow transplant recipients: autopsy findings. 
Chest 2005; 128:1385–92.
